These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1180 related items for PubMed ID: 16149676

  • 21. Phase III study of two different dosing schedules of erythropoietin in anemic patients with cancer.
    Steensma DP, Molina R, Sloan JA, Nikcevich DA, Schaefer PL, Rowland KM, Dentchev T, Novotny PJ, Tschetter LK, Alberts SR, Hogan TF, Law A, Loprinzi CL.
    J Clin Oncol; 2006 Mar 01; 24(7):1079-89. PubMed ID: 16505427
    [Abstract] [Full Text] [Related]

  • 22. Weekly administration of epoetin beta for chemotherapy-induced anemia in cancer patients: results of a multicenter, Phase III, randomized, double-blind, placebo-controlled study.
    Tsuboi M, Ezaki K, Tobinai K, Ohashi Y, Saijo N.
    Jpn J Clin Oncol; 2009 Mar 01; 39(3):163-8. PubMed ID: 19164318
    [Abstract] [Full Text] [Related]

  • 23. Epoetin Beta once-weekly therapy in anemic patients with solid tumors and non-myeloid hematological malignancies receiving chemotherapy.
    Spaëth D, Desablens B, Rodon P, Mennecier B, Oudard S, Moullet I, Ghomari K, Bergougnoux L, Bleuzen P, Jenabian A, Ifrah N.
    Oncology; 2008 Mar 01; 74(1-2):112-8. PubMed ID: 18547966
    [Abstract] [Full Text] [Related]

  • 24. Response predicting factors to recombinant human erythropoietin in cancer patients undergoing platinum-based chemotherapy.
    González-Barón M, Ordóñez A, Franquesa R, Constenla M, Montalar J, Gili F, Camps C, Sancho JF, Pérez-Cachot P.
    Cancer; 2002 Dec 01; 95(11):2408-13. PubMed ID: 12436449
    [Abstract] [Full Text] [Related]

  • 25. The impact of weekly dosing of epoetin alfa on the haematological parameters and on the quality of life of anaemic cancer patients.
    Heras P, Argyriou AA, Papapetropoulos S, Karagiannis S, Argyriou K, Mitsibounas D.
    Eur J Cancer Care (Engl); 2005 May 01; 14(2):108-12. PubMed ID: 15842457
    [Abstract] [Full Text] [Related]

  • 26. Relationship between hemoglobin level and quality of life in anemic patients with chronic kidney disease receiving epoetin alfa.
    Lefebvre P, Vekeman F, Sarokhan B, Enny C, Provenzano R, Cremieux PY.
    Curr Med Res Opin; 2006 Oct 01; 22(10):1929-37. PubMed ID: 17022852
    [Abstract] [Full Text] [Related]

  • 27. Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa.
    Dieterich DT, Wasserman R, Bräu N, Hassanein TI, Bini EJ, Bowers PJ, Sulkowski MS.
    Am J Gastroenterol; 2003 Nov 01; 98(11):2491-9. PubMed ID: 14638354
    [Abstract] [Full Text] [Related]

  • 28. Recombinant human erythropoietin beta therapy: an effective strategy to reduce transfusion requirement in children receiving anticancer treatment.
    Corapcioglu F, Aksu G, Basar EZ, Demirel A, Oncel S, Mutlu A.
    Pediatr Hematol Oncol; 2008 Sep 01; 25(6):509-21. PubMed ID: 18728970
    [Abstract] [Full Text] [Related]

  • 29. Randomized, open-label comparison of epoetin alfa extended dosing (80 000 U Q2W) vs weekly dosing (40 000 U QW) in patients with chemotherapy-induced anemia.
    Henry DH, Gordan LN, Charu V, Wilhelm FE, Williams D, Xie J, Woodman RC.
    Curr Med Res Opin; 2006 Jul 01; 22(7):1403-13. PubMed ID: 16834839
    [Abstract] [Full Text] [Related]

  • 30. Effect of epoetin alfa on survival and cancer treatment-related anemia and fatigue in patients receiving radical radiotherapy with curative intent for head and neck cancer.
    Hoskin PJ, Robinson M, Slevin N, Morgan D, Harrington K, Gaffney C.
    J Clin Oncol; 2009 Dec 01; 27(34):5751-6. PubMed ID: 19884550
    [Abstract] [Full Text] [Related]

  • 31. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
    Sulowicz W, Locatelli F, Ryckelynck JP, Balla J, Csiky B, Harris K, Ehrhard P, Beyer U, PROTOS Study Investigators.
    Clin J Am Soc Nephrol; 2007 Jul 01; 2(4):637-46. PubMed ID: 17699476
    [Abstract] [Full Text] [Related]

  • 32. Clinical benefits of two different dosing schedules of recombinant human erythropoietin in anemic patients with advanced head and neck cancer.
    Gupta S, Singh PK, Bhatt ML, Pant MC, Sundar S, Verma J, Paul S, Kumar D, Shah A, Gupta R, Negi MP.
    Biosci Trends; 2010 Oct 01; 4(5):267-72. PubMed ID: 21068481
    [Abstract] [Full Text] [Related]

  • 33. Therapeutic equivalence of epoetin zeta and alfa, administered subcutaneously, for maintenance treatment of renal anemia.
    Krivoshiev S, Wizemann V, Czekalski S, Schiller A, Pljesa S, Wolf-Pflugmann M, Siebert-Weigel M, Koytchev R, Bronn A, Epoetin Zeta Study Group.
    Adv Ther; 2010 Feb 01; 27(2):105-17. PubMed ID: 20369312
    [Abstract] [Full Text] [Related]

  • 34. Early intervention with epoetin beta prevents severe anaemia in lung cancer patients receiving platinum-based chemotherapy: a subgroup analysis of the NeoPrevent study.
    de Castro J, Belda-Iniesta C, Isla D, Dómine M, Sánchez A, Batiste E, Barón MG.
    Lung Cancer; 2008 Feb 01; 59(2):211-8. PubMed ID: 17875340
    [Abstract] [Full Text] [Related]

  • 35. Anaemia management with epoetin alfa in lung cancer patients in The Netherlands.
    Biesma B, van de Werf PR, Melissant CF, Brok RG.
    Lung Cancer; 2007 Oct 01; 58(1):104-11. PubMed ID: 17601632
    [Abstract] [Full Text] [Related]

  • 36. Initiation of epoetin-alpha therapy at a starting dose of 120,000 units once every 3 weeks in patients with cancer receiving chemotherapy: an open-label, multicenter study with randomized and nonrandomized treatment arms.
    Glaspy JA, Charu V, Luo D, Moyo V, Kamin M, Wilhelm FE.
    Cancer; 2009 Mar 01; 115(5):1121-31. PubMed ID: 19170225
    [Abstract] [Full Text] [Related]

  • 37. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study.
    Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S, Manikhas G, Makhson A, Roth A, Dodwell D, Baselga J, Biakhov M, Valuckas K, Voznyi E, Liu X, Vercammen E.
    J Clin Oncol; 2005 Sep 01; 23(25):5960-72. PubMed ID: 16087945
    [Abstract] [Full Text] [Related]

  • 38. Once-weekly epoetin beta (30,000 IU) in anemic patients with lung cancer receiving chemotherapy.
    Pirker R, Lehnert M, Minar W.
    Lung Cancer; 2007 Jan 01; 55(1):89-94. PubMed ID: 17084484
    [Abstract] [Full Text] [Related]

  • 39. A new dose-intense epoetin alfa regimen effective in anemic cancer patients receiving chemotherapy: an open-label, non randomized, pilot study.
    Santini D, Vincenzi B, La Cesa A, Virzi V, Navajas F, Malafarina V, Dicuonzo G, Cassandro R, Esposito V, Montesarchio V, Groeger AM, Tonini G.
    Anticancer Res; 2005 Jan 01; 25(1B):669-74. PubMed ID: 15816644
    [Abstract] [Full Text] [Related]

  • 40. Early intervention with epoetin beta prevents severe anaemia in patients with solid tumours receiving platinum-based chemotherapy: results of the NeoPrevent study.
    de Castro J, Ordóñez A, Isla D, Sánchez A, Arrivi A, Manzano JL, Barón MG.
    Cancer Chemother Pharmacol; 2007 Jan 01; 59(1):35-42. PubMed ID: 16874498
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 59.